Zhitong Finance App News, Kexing Pharmaceutical (688136.SH) issued an announcement. Recently, Shenzhen Kexing Pharmaceutical Co., Ltd. (“Shenzhen Kexing” for short), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the State Drug Administration approved the TL1A monoclonal antibody innovative drug “GB20 injection” independently developed by Shenzhen Kexing to conduct clinical trials.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Kexing Pharmaceutical (688136.SH) issued an announcement. Recently, Shenzhen Kexing Pharmaceutical Co., Ltd. (“Shenzhen Kexing” for short), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the State Drug Administration approved the TL1A monoclonal antibody innovative drug “GB20 injection” independently developed by Shenzhen Kexing to conduct clinical trials.